Shots:
- The EC has approved an extension of the indication of MenQuadfi to incl. infants (≥6wks.) for protection against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, & Y
- Approval was supported by extensive data from the MET58 clinical study, which evaluated the immunogenicity, safety, & tolerability of MenQuadfi in infants from 6wks. of age
- MenQuadfi (Meningococcal Group A, C, W and Y conjugate vaccine) was previously approved in the EU for individuals aged ≥12mos.
Ref: Globenewswire | Image: Sanofi | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
